Please login to the form below
Alessandro Riva
This page shows the latest Alessandro Riva news and features for those working in and with pharma, biotech and healthcare.
Riva leaves Gilead to head Glenmark’s innovation spin-off
Company has own bispecific antibody platform. Indian pharma company Glenmark has appointed Alessandro Riva as the chief executive of its new spin-off company focused on innovative medicines. ... In a statement, Riva said he was excited to join a company
Latest news
-
Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
Alessandro Riva, MD, Gilead's executive vice president, Oncology Therapeutics &Head, Cell Therapy said: “This research collaboration adds an additional new platform to our current capabilities in research and cell manufacturing,
-
Novartis seeks first-line use for lung cancer drug Zykadia
Zykadia has proven to be an important treatment option for ALK+ NSCLC patients who have progressed following treatment with crizotinib," said Novartis head of oncology development and medical affairs, Alessandro Riva.
-
Novartis claims FDA breakthrough status for leukaemia treatment
established. Alessandro Riva, managing director and global head for Novartis' oncology development and medical affairs, said: “For more than 25 years, medical developments have been limited for AML patients and the
-
FDA needs more time to review Novartis’ cancer drug
Alessandro Riva, global head of oncology development and medical affairs for Novartis's oncology business, said: "We are committed to working with the FDA as they continue to review the LBH589
-
Novartis plans filings for acromegaly candidate
Alessandro Riva, interim president of Novartis Oncology and global head of oncology development and medical affairs, said: "These results strengthen our understanding of this rare endocrine disorder and suggest pasireotide LAR
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics
Gilead Sciences has promoted Dr Alessandro River from senior vice president, haematology and oncology therapeutic area head, to executive vice president, oncology therapeutics. ... Dr Riva joined the biopharmaceutical group in January 2017, and his
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Takeda’s dengue vaccine receives MHRA approval for those aged four years and older
- Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
- Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients
- NHS urges people yet to receive their COVID-19 booster to come forward
- Biosimilars and beyond: innovating for improved patient outcomes
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Why female mentorship is so powerful in pharma
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Digital technology: a significant change in healthcare innovation
- Assessing the value of interim analyses in clinical trials
PMHub
Dovetail
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...
Latest intelligence
- Biosimilars and beyond: innovating for improved patient outcomes
- How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
